Clinical Trial

Phase 3 Clinical Trial of Buagafuran Capsules in the Treatment of GAD

Name: Phase 3 Clinical Trial of Buagafuran Capsules in the Treatment of GAD — clinical trial record (NCT06243640)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: BGFN-2022-02

Recruiting Phase 3

View on ClinicalTrials.gov →

Record status

This record was last updated February 6, 2024 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.

Summary

A placebo-controlled superiority design was used to evaluate the efficacy of 60 mg/ day or 120 mg/ day of Buagafuran capsules in the treatment of GAD

Trial Details

NCT Number	NCT06243640
Lead Sponsor	Beijing Union Pharmaceutical Factory Ltd Collaborators: R&G Pharma Studies Co.,Ltd.
Conditions	Generalized Anxiety Disorder
Enrollment	504 participants
Start Date	2023-07-25
Primary Completion	2026-06-30 (estimated)
Study Completion	2027-06-30 (estimated)
Updated on ClinicalTrials.gov	2024-02-06